Pharmacokinetics of the novel atypical opioid tapentadol after intravenous, intramuscular and subcutaneous administration in cats

Veterinary Journal

Volumn 198, Issue 3, 2013, Pages 620-624

  Lee, H K ^a   Lebkowska Wieruszewska B ^b   Kim, T W ^a   Kowaski, C J ^b   Giorgi, M ^c  

^a Chungnam National University   (South Korea)

^b UNIVERSITY OF LIFE SCIENCES IN LUBLIN   (Poland)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

Bioavailability; Cats; Intramuscular; Pharmacokinetics; Subcutaneous; Tapentadol

Indexed keywords

TAPENTADOL;

AGITATION; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CAT; CLINICAL EVALUATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MEAN RESIDENCE TIME; NONHUMAN; SALIVATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALIA;

BIOAVAILABILITY; CATS; INTRAMUSCULAR; PHARMACOKINETICS; SUBCUTANEOUS; TAPENTADOL;

ANALGESICS, OPIOID; ANIMALS; CATS; CROSS-OVER STUDIES; FEMALE; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; PHENOLS;

EID: 84888435951     PISSN: 10900233     EISSN: 15322971     Source Type: Journal    
DOI: 10.1016/j.tvjl.2013.09.011     Document Type: Article

References (27)

1. Barnhart M.D., Hubbell J.A., Muir W.W., Sams R.A., Bednarski R.M. Pharmacokinetics, pharmacodynamics, and analgesic effects of morphine after rectal, intramuscular, and intravenous administration in dogs. American Journal of Veterinary Research 2000, 61:24-28.
2. Boothe D.M. Drug therapy in cats: Mechanisms and avoidance of adverse drug reactions. Journal of the American Veterinary Medical Association 1990, 196:1297-1305.
3. Clutton R.E. Opioid analgesia in horses. Veterinary Clinics of North America: Equine Practice 2010, 26:493-514.
4. Court M.H., Greenblatt D.J. Molecular basis for deficient acetaminophen glucuronidation in cats. An interspecies comparison of enzyme kinetics in liver microsomes. Biochemical Pharmacology 1997, 53:1041-1047.
5. Etropolski M., Kelly K., Okamoto A., Rauschkolb C. Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride. Advances in Therapy 2011, 28:401-417.
6. Fox M.S. Chronic Pain in Small Animal Medicine 2010, Mason Publishing, London, UK, pp. 113-137.
7. Gabrielsson J., Weiner D. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications 2002, Swedish Pharmaceutical Press, Stockholm, Sweden, pp. 141-151.
8. Giorgi M., Del Carlo S., Łebkowska-Wieruszewska B., Kowalski C.J., Saccomanni G. Pharmacokinetics of tramadol and metabolites after injective administrations in dogs. Polish Journal of Veterinary Sciences 2010, 13:639-644.
9. Giorgi M., Yun H. Pharmacokinetics of mirtazapine and its main metabolites in Beagle dogs: A pilot study. The Veterinary Journal 2012, 192:239-241.
10. Giorgi M. Pharmacokinetic differences of tramadol in several animal species and human beings. Journal of Veterinary Research 2008, 63:1-4.
11. Giorgi M. Tramadol vs. tapentadol: A new horizon in pain treatment?. American Journal of Animal and Veterinary Sciences 2012, 7:7-11.
12. Giorgi M., Del Carlo S., Saccomanni G., Łebkowska-Wieruszewska B., Turini V., Kowalski C. Biopharmaceutical profile of tramadol in the dog. Veterinary Research Communications 2009, 33:S189-S192.
13. Giorgi M., Meizler A., Mills P.C. Pharmacokinetics of the novel atypical opioid tapentadol after oral and intravenous administration in dogs. The Veterinary Journal 2012, 194:309-313.
14. Giorgi M., Meizler A., Mills P.C. Detection and quantification of the novel opioid drug tapentadol in canine plasma by HPLC with spectrofluorimetric detection: Development and validation of a new methodology. Journal of Pharmaceutical and Biomedical Analysis 2012, 67-68:148-153.
15. Giorgi M., Mills P.C., Tayari H., Rota S., Breghi G., Briganti A. Plasma concentrations of tapentadol and clinical evaluations of a combination of tapentadol plus sevoflurane for surgical anaesthesia and analgesia in rabbits (Oryctolagus cuniculus) undergoing orchiectomy. Israel Journal of Veterinary Medicine 2013, 68:141-148.
16. Kleinert R., Lange C., Steup A., Black P., Goldberg J., Desjardins P. Single dose analgesic efficacy of tapentadol in postsurgical dental pain: The results of a randomized, double-blind, placebo-controlled study. Anesthesia and Analgesia 2008, 107:2048-2055.
17. Lascelles B.D.X., Capner C.A., Waterman-Pearson A.E. Current British veterinary attitudes to perioperative analgesia for cats and small mammals. Veterinary Record 1999, 145:601-604.
18. McMillan C.J., Livingston A., Clark C.R., Dowling P.M., Taylor S.M., Duke T., Terlinden R. Pharmacokinetics of intravenous tramadol in dogs. Canadian Journal of Veterinary Research 2008, 72:325-331.
19. KuKanich B., Papich M. Opioid analgesic drugs. Veterinary Pharmacology and Therapeutics 2009, 301-335. Wiley Blackwell, Ames, IO, USA. M. Papich, J. Riviere (Eds.).
20. Pascoe P.J. Opioid analgesics. Veterinary Clinics of North America: Small Animal Practice 2000, 30:757-772.
21. Raffa R.B., Friderichs E., Reimann W., Shank R.P., Codd E.E., Vaught J.L. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. Journal of Pharmacology and Experimental Therapeutics 1992, 260:275-285.
22. Taylor P.M., Robertson S.A., Dixon M.J., Ruprah M., Sear J.W., Lascelles B.D.X., Waters C., Bloomfield M. Morphine, pethidine and buprenorphine disposition in the cat. Journal of Veterinary Pharmacology and Therapeutics 2001, 24:391-398.
23. Toutain P.L., Lees P. Integration and modelling of pharmacokinetic and pharmacodynamic data to optimize dosage regimens in veterinary medicine. Journal of Veterinary Pharmacology and Therapeutics 2004, 27:467-477.
24. Tzschentke T.M., Christoph T., Kögel B., Schiene K., Hennies H.H., Englberger W., Haurand M., Jahnel U., Cremers T.I., Friderichs E., et al. (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): A novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. Journal of Pharmacology and Experimental Therapeutics 2007, 323:265-276.
25. Tzschentke T.M., Jahnel U., Kögel B., Christoph T., Englberger W., De Vry J., Schiene K., Okamoto A., Upmalis D., Weber H., et al. Tapentadol hydrochloride: A next-generation, centrally acting analgesic with two mechanisms of action in a single molecule. Drugs Today 2009, 45:483-496.
26. Vadivelu N., Mitra S., Hines R.L. Peripheral opioid receptor agonists for analgesia: A comprehensive review. Journal of Opioid Management 2011, 7:55-68.
27. Xu X.S., Smit J.W., Lin R., Stuyckens K., Terlinden R., Nandy P. Population pharmacokinetics of tapentadol immediate release (IR) in healthy subjects and patients with moderate or severe pain. Clinical Pharmacokinetics 2010, 49:671-682.